Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.37 |
| ▸ | BCL2L11 | O43521 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.35 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.34 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26194440 | 0.84 | SMN1; SMN2 (0.39) | KDM1ASIGMAR1KDM4CMCL1BCL2L11 | |
| SCHEMBL21930213 | 0.84 | SIGMAR1 (0.42) | KDM1ASIGMAR1KDM4CMCL1BCL2L11 | |
| SCHEMBL21930565 | 0.84 | SIGMAR1 (0.42) | KDM1ASIGMAR1KDM4CMCL1BCL2L11 | |
| SCHEMBL17542330 | 0.82 | KDM1A (0.37) | KDM1ASIGMAR1KDM4CMCL1BCL2L11 | |
| SCHEMBL17542332 | 0.82 | KDM1A (0.37) | KDM1ASIGMAR1KDM4CMCL1BCL2L11 | |
| SCHEMBL23442101 | 0.81 | KDM1A (0.41) | KDM1ASIGMAR1KDM4CMCL1SMN1; SMN2 | |
| SCHEMBL17542383 | 0.79 | ALDH1A1 (0.38) | KDM1ASIGMAR1KDM4CSMN1; SMN2HPGD | |
| SCHEMBL17542382 | 0.79 | ALDH1A1 (0.38) | KDM1ASIGMAR1KDM4CSMN1; SMN2HPGD | |
| SCHEMBL28964369 | 0.78 | SIGMAR1 (0.46) | KDM1ASIGMAR1KDM4CBACE1 | |
| SCHEMBL23442105 | 0.78 | KDM1A (0.39) | KDM1ASIGMAR1KDM4CMCL1BCL2L11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760736-B2 | Processes and intermediates for preparing MCL1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11760736-B2 | Processes and intermediates for preparing MCL1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230013713-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-01-19 | — | — | US | disclosed |
| US-20220177409-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS | GILEAD SCIENCES, INC. | 2022-06-09 | — | — | US | disclosed |
| WO-2022108984-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING MACROCYCLIC MCL1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| US-11325891-B2 | Processes and intermediates for preparing MCL1 inhibitors | GILEAD SCIENCES, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-20210179570-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS | GILEAD SCIENCES, INC. | 2021-06-17 | — | — | US | disclosed |
| WO-2021108254-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2021-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177409-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS | MCL1, BCL3, XIAP | KDM1A 1660/4885SIGMAR1 4042/4885KDM4C 2954/4885 |
| US-11760736-B2 | Processes and intermediates for preparing MCL1 inhibitors | MCL1, BAK1, BCL3 | KDM1A 563/4885SIGMAR1 4148/4885KDM4C 2667/4885 |
| US-20210179570-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS | MCL1, BAK1, BCL3 | KDM1A 563/4885SIGMAR1 4148/4885KDM4C 2667/4885 |
| US-11325891-B2 | Processes and intermediates for preparing MCL1 inhibitors | MCL1, BAK1, BCL3 | KDM1A 563/4885SIGMAR1 4148/4885KDM4C 2667/4885 |
| US-20230013713-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS | MCL1, BAK1, BCL3 | KDM1A 563/4885SIGMAR1 4148/4885KDM4C 2667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.